Main Article Content
Abstract
Background: Diabetes mellitus patients may have a different response to
similar medication. Therefore, individualized treatment and monitoring
of the therapy is needed to ensure the patients’ response. Alternative
medication or dose adjustment should be considered in order to achieve
the therapeutic goal.
Objective: The aim of this study was to find out patients’ response to
medication variation or dose adjustment.
Methods: This study used descriptive design in PKU Muhammadiyah
Hospital and Panti Rapih hospital period October-December 2014.
Participants are all patients who got pharmacological therapy for treatment
of diabetes mellitus type 2, including oral antidiabetics and/ insulin and
met the inclusion criteria. The response of therapy was checked 2 times,
during check-in and check-out.
Results: Analysis of response variation showed that individualized
response existed, in which positive response occurred in 10 patients and
the other had a negative response. The changes were dose adjustment
and medication alteration or medication addition. From 6 patients who
needed medication adjusment, 5 patients had a positive response, and
others had a negative response. Whereas from 6 patients whose dosage or
medication was not changed, 5 of them had a positive response while one
had a negative response.
Conclusion: Individualized treatment is needed to achieve a therapeutic
goal. Individualized treatment can be done through dose adjustment and
medication alteration, or medications addition.
Article Details
References
- International Diabetes Federation. IDF Diabetes Atlas. 6th ed. International Diabetes Federation; 2013.
- Departemen Kesehatan RI. Pharmaceutical Care Untuk Penyakit Diabetes Mellitus. Jakarta: Departemen Kesehatan RI; 2005.
- Becker ML, Pearson ER, Tkac I. Review article?: Pharmacogenetics of oral antidiabetic drugs. International Journal of Endocrinology. 2013;2013:1–10.
- Hoeger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31(1):81–6.
- DiStefano JK, Watanabe RM. Review: Pharmacogenetics of anti-diabetes drugs. Pharmaceuticals. 2010;3(8):2610–46.
- Huri HZ, Xiang LT. Factors associated with treatment response to antidiabetic agents in compliant Type 2 Diabetes Mellitus patients: A brief summary of 5-year data. Tropical Journal of Pharmaceutical Research. 2014;13(3):429–35.
- Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1C after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2011;13(6):542–50.
- Schroner Z, Javorsky M, Kozarova M, Tkac I. Review pharmacogenetics of oral antidiabetic treatment. Bratisl Lek Listy. 2011;112(8):441–6.
- Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, et al. A common 5’-UTR variant in MATE2-K is associated with poor response to metformin. Clinical Pharmacology and Therapeutics. 2011;90(5):674–84.
- Topic E. The Role of pharmacogenetics in the treatment of Diabetes Mellitus. Journal of Medical Biochemistry. 2014;33(1):58–70.
- Acquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: The influence of drug target and diabetes risk polymorphisms. Expert Review of Cardiovascular Therapy. 2010;8(3):359–72.
References
International Diabetes Federation. IDF Diabetes Atlas. 6th ed. International Diabetes Federation; 2013.
Departemen Kesehatan RI. Pharmaceutical Care Untuk Penyakit Diabetes Mellitus. Jakarta: Departemen Kesehatan RI; 2005.
Becker ML, Pearson ER, Tkac I. Review article?: Pharmacogenetics of oral antidiabetic drugs. International Journal of Endocrinology. 2013;2013:1–10.
Hoeger TJ, Segel JE, Gregg EW, Saaddine JB. Is glycemic control improving in U.S. adults? Diabetes Care. 2008;31(1):81–6.
DiStefano JK, Watanabe RM. Review: Pharmacogenetics of anti-diabetes drugs. Pharmaceuticals. 2010;3(8):2610–46.
Huri HZ, Xiang LT. Factors associated with treatment response to antidiabetic agents in compliant Type 2 Diabetes Mellitus patients: A brief summary of 5-year data. Tropical Journal of Pharmaceutical Research. 2014;13(3):429–35.
Forst T, Uhlig-Laske B, Ring A, Ritzhaupt A, Graefe-Mody U, Dugi KA. The oral DPP-4 inhibitor linagliptin significantly lowers HbA1C after 4 weeks of treatment in patients with type 2 diabetes mellitus. Diabetes, Obesity and Metabolism. 2011;13(6):542–50.
Schroner Z, Javorsky M, Kozarova M, Tkac I. Review pharmacogenetics of oral antidiabetic treatment. Bratisl Lek Listy. 2011;112(8):441–6.
Choi JH, Yee SW, Ramirez AH, Morrissey KM, Jang GH, Joski PJ, et al. A common 5’-UTR variant in MATE2-K is associated with poor response to metformin. Clinical Pharmacology and Therapeutics. 2011;90(5):674–84.
Topic E. The Role of pharmacogenetics in the treatment of Diabetes Mellitus. Journal of Medical Biochemistry. 2014;33(1):58–70.
Acquilante CL. Sulfonylurea pharmacogenomics in Type 2 diabetes: The influence of drug target and diabetes risk polymorphisms. Expert Review of Cardiovascular Therapy. 2010;8(3):359–72.